Business
Bioretec clarifies its 2026-2028 financial target regarding the sales margin
To be aligned with industry reporting standards, Bioretec will transition to reporting an adjusted sales margin from Q1/2026 onwards, as compared to the previously reported sales margin. The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions. This change improves the transparency of Bioretec's performance in its core business and ensures alignment with industry practices.
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Company release 13 May 2026 at 14:00 p.m. EEST","length":64,"tagName":"p"},{"type":"text","content":"HELSINKI, May 13, 2026 /PRNewswire/ -- To be aligned with industry reporting standards, Bioretec will transition to reporting an adjusted sales margin from Q1/2026 onwards, as compared to the previously reported sales margin. The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions. This change improves the transparency of Bioretec's performance in its core business and ensures alignment with industry practices.","length":502,"tagName":"p"},{"type":"text","content":"The calculation formula of the previously reported sales margin was total net sales (including implants and instruments) less the change in inventories and materials and services. Going forward, the net sales component will only include the net sales from implants, and items recognised below the adjusted sales margin will include, among others, commissions and external services considered fixed in nature.","length":408,"tagName":"p"},{"type":"text","content":"In line with the reporting change, the second financial target for the strategy period 2026-2028 will be updated to concern the adjusted sales margin instead of the previously reported sales margin.","length":198,"tagName":"p"},{"type":"text","content":"Bioretec's updated financial targets for the strategy period 2026-2028 are:","length":79,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reach net sales exceeding EUR 10 million by the end of the year 2028","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Maintain an average adjusted sales margin exceeding 70% during the strategy period","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":150,"olType":false},{"type":"text","content":"The targets previously announced on 16 December 2025 for the 2026-2028 strategy period were:","length":92,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reach net sales exceeding EUR 10 million by the end of the year 2028","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Maintain an average sales margin exceeding 70% during the strategy period","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":141,"olType...